/PRNewswire/ -- ZyVersa Therapeutics, Inc. ("ZyVersa"), a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to...
Annual Inflammasome Summit unites world renowned experts in inflammasome-targeted drug development and academia to share information and address knowledge gaps...
Special meeting of Larkspur stockholders scheduled for December 8, 2022, to vote on the proposed business combination of Larkspur with ZyVersa ZyVersa is a...
Mr. Glover will be joining four other life science executives in a General Session titled, CEO Panel: Learn from the experts ZyVersa is a clinical stage...
Aggregate committed financing in support of the business combination now at $10.0 million ZyVersa and Larkspur entered into a definitive business combination...
Age-related chronic inflammation induced by activation of NLRP1 inflammasomes is implicated in development and progression of neurodegenerative diseases such...
/PRNewswire/ -- Larkspur Health Acquisition Corp. (NASDAQ: LSPR or "Larkspur"), a blank-check special purpose acquisition company, and ZyVersa Therapeutics,...
/PRNewswire/ -- ZyVersa Therapeutics, Inc., (ZyVersa) a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of...